Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Extended-release divalproex sodium for mood stabilization.

Steven C Stoner1, Beth M Dubisar, Jessica W Lea

  • 1University of Missouri-Kansas City Schools of Pharmacy and Medicine, Kansas City, MO 64506, USA. stoners@umkc.edu

Pharmacotherapy
|October 6, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Value of Conditional Release for Insanity Acquittees.

The journal of the American Academy of Psychiatry and the Law·2023
Same author

Inpatient prescribing patterns of long-acting injectables and their oral or short-acting injectable equivalent formulations.

Frontiers in pharmacology·2023
Same author

Community Pharmacist Telephonic Medication Reviews with Uncontrolled Asthma Patients: A Pilot Study.

Pharmacy (Basel, Switzerland)·2021
Same author

Initiative to improve student perceptions of relevance and value in a top 200 drugs course through improved curricular alignment and course modification.

Currents in pharmacy teaching & learning·2020
Same author

Evaluation of obsessive-compulsive symptoms in relation to smartphone use.

The mental health clinician·2020
Same author

Impact of community pharmacist-performed post-discharge medication reviews in transitions of care.

Journal of the American Pharmacists Association : JAPhA·2018

Switching patients with mood disorders from delayed-release to extended-release divalproex sodium improved tolerability. This transition reduced adverse effects like sedation, stomach upset, and tremor, suggesting a beneficial alternative for mood lability management.

Area of Science:

  • Psychopharmacology
  • Neuroscience
  • Clinical Therapeutics

Background:

  • Divalproex sodium is a widely used antiepileptic and mood-stabilizing drug.
  • Delayed-release formulations of divalproex sodium can be associated with gastrointestinal and other adverse effects.
  • Extended-release formulations aim to improve drug tolerability and patient compliance.

Purpose of the Study:

  • To evaluate the efficacy, safety, and tolerability of switching from delayed-release to extended-release divalproex sodium.
  • To assess the impact of this formulation switch on psychiatric symptoms and adverse events in patients with mood or thought disorders.

Main Methods:

  • A prospective, open-label, 4-week study was conducted in a long-term care facility.
  • Ten hospitalized patients with mood or thought disorders experiencing adverse effects from delayed-release divalproex sodium were enrolled.

Related Experiment Videos

  • Participants were switched from delayed-release to an equivalent dose-adjusted extended-release formulation of divalproex sodium.

    • Main Results:

    • No significant changes were observed in Brief Psychiatric Rating Scale (BPRS) scores, though a trend towards decreased somatic complaints was noted.
    • Serum valproic acid concentrations remained stable after the switch (90.5 mg/L vs 95.5 mg/L).
    • Significant reductions in sedation (p=0.022), stomach or abdominal discomfort (p=0.045), and tremor (p=0.004) were reported post-conversion.

    Conclusions:

    • This preliminary study suggests successful conversion from delayed-release to extended-release divalproex sodium in patients with mood lability.
    • The transition to the extended-release formulation was associated with a significant decrease in common adverse effects.
    • Extended-release divalproex sodium may offer improved tolerability for patients experiencing side effects with the delayed-release form.